Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
In a landmark Phase 2 trial, patients receiving the highest dose of retatrutide (12 mg) achieved an average weight loss of 24.2% after 48 weeks
Potential Advantages Dosing convenience: Once or twice weekly injections versus multiple daily doses Consistent IGF-1 elevation: No peaks and troughs between doses Simplicity: Fewer variables to manage in research protocols Proven human data: Phase I/II clinical trials demonstrated safety and efficacy for GH/IGF-1 elevation Potential Concerns Non-physiological GH pattern: Sustained stimulation may lead to receptor desensitization over time Cortisol and prolactin elevation: Some research reports increased cortisol and prolactin as side effects of sustained GHRH stimulation Difficulty adjusting dose: Once injected, the long half-life means effects cannot be quickly reversed GH bleed: The constant presence may blunt the body's natural GH pulses rather than enhance them CJC-1295 Without DAC (Mod GRF 1-29): Pulsatile GH Release Pharmacokinetics CJC-1295 without DACmore accurately called Modified GRF (1-29) or Mod GRF 1-29retains the four amino acid substitutions that protect it from rapid enzymatic degradation but lacks the albumin-binding DAC component
A literature and patent review published in Pharmaceuticals (MDPI) summarizes that BPC-157 demonstrates a desirable safety profile in preclinical research, with only a few side effects reported across animal studies, and documents its broad activity across tissue injury, inflammatory and CNS-adjacent research models via VEGFR2-Akt-eNOS angiogenic pathways and nitric oxide signaling
For adults running a standard protocol, it's fine, and it's the standard choice
US$ 20.51
US$ 25.87
US$ 20.89
US$ 28.62
US$ 22.09
US$ 23.34
US$ 25.62
US$ 21.16
US$ 27.51
